Meet the CMA AsiaPac Team
Adam Gordois, Director, Health Economics BA (Hons), MSc Health Econ
Adam Gordois has over 18 years of health economics consulting experience in Australia and the UK spanning the pharmaceutical and medical devices industries, government, and not-for-profit organisations. His areas of special expertise include market access and reimbursement support, healthcare technology and policy assessment, cost-effectiveness modelling and forecasting. Adam has published in and provided peer reviews for a variety of health economics and clinical journals, and from 2006 to 2015 ran the Pharmacoeconomics course of the MMedSc Drug Development program at the University of NSW.
Prior to joining Labcorp Drug Development, Adam was Director of Health Economics and Social Policy at Deloitte Access Economics in Sydney following senior health economics roles at IMS (Australia), and a Research Fellow role at the York Health Economics Consortium, UK. Adam received an MSc in Health Economics (Distinction) from the University of York, and a BA in Business Economics (First Class Honours) from the University of Leicester.
Sam Colman, Director, HEOR, BEc, BSc (Hons), MBiostat
Sam Colman has over 18 years of experience as a statistician in government, academia, and industry, including 11 years in the pharmaceutical industry. He has expertise in several therapeutic areas including oncology, endocrine, neuroscience, cardiovascular disease and respiratory disease. Sam has designed and analysed a significant number of trial types including parallel randomised controlled trials, observational, cross-over, case-control, sample surveys, meta-analyses, and chart audits, and he has experience in all phases of clinical development (Phase I to Phase IV).
Sam has a strong health economics and outcomes research background with expertise in meta-analysis, indirect comparisons, and area-under-the-curve estimates and has worked on a number of successful PBAC submissions in Australia. Sam received a BEc and a BSc (Honours, Statistics) from the Australian National University and a Masters of Biostatistics from the University of Sydney.
Carol Lee, Senior Manager, BPharm, Dip. Hosp. Pharm., Grad Cert Pharmacoeconomics.
Carol’s expertise and interest includes assistance in the strategy development of reimbursement submissions of pharmaceuticals to the Australian and New Zealand Governments, feasibility studies of innovative medical devices and health outcomes.
Prior to joining the Market Access Services group, Carol held clinical roles at Janssen-Cilag and regulatory and health economic roles at Sandoz (now Novartis). Carol also has experience working in retail and hospital pharmacy. Carol received her BPharm and Dip. Hosp Pharm from the University of Sydney and Graduate Certificate of Pharmacoeconomics from Monash University.
Karen Schneider, Manager, BSc (Hons), MPH, PhD
Karen Schneider has over 8 years of experience in health economics for pharmaceutical and medical devices companies, academia, and other not-for-profit organisations. Karen’s area of special expertise is economic modelling, including cost-effectiveness, cost-utility, infectious disease and budget-impact modelling. Karen also specialises in market access strategy and the development of pharmaceutical reimbursement submissions to authorities including the PBAC in Australia and PHARMAC in New Zealand.
Prior to joining Labcorp Drug Development in 2011, Karen held research roles with the National Association of People Living with HIV/AIDS (NAPWA), the Kirby Institute for Infection and Immunity in Society, the University of New South Wales (UNSW), and the School of Public Health and Community Medicine (SPHCM), UNSW. Karen was awarded her PhD from the University of New South Wales in 2013. Her area of research was the cost-effectiveness of treatment and prevention strategies in HIV. In addition, Karen was awarded a Master of Public Health from Sydney University and a Bachelor of Science (Hons) from the UNSW and Macquarie University.
Dante Kemp, Manager, MSc Biostatistics
Dante Kemp has over 8 years of experience working in health economics and biostatistics. At Labcorp Drug Development, Dante specialises in the development of economic models and the provision of statistical analyses. He manages health economics projects such as reimbursement submissions, evidence based literature reviews, retrospective and prospective collection of outcome and resource data, and pricing analyses. He also conducts statistical analyses including writing of statistical analysis plans, data management in SAS/STATA/Excel/VBA, development of statistical models, clinical trial design, and analysis of clinical trial data.
Prior to joining Labcorp Drug Development in 2018, Dante worked as a statistician at John Wlodarczyk Consulting Services. His work there included planning and conducting the analysis of clinical trials, writing clinical study reports, developing global economic models, and supporting reimbursement submissions internationally. Dante’s was part of the first successful submission of a co-dependent technology in Australia, and his modelling approach was subsequently the standard in Australia. He has published on the association between cancer and immuno-suppression, and on the predictive factors and outcomes of bleeding complications following coronary intervention. Dante holds a Master’s of Science in Biostatistics from the New Jersey Institute of Technology, and a Bachelor’s of Science in Biochemistry from Rutger’s University.
Oona Reardon, Associate Manager, BSc (Hons), MPH
Oona has several years’ experience in health economics within consulting, academic and industry sectors. Oona’s areas of expertise include critical appraisal of clinical trials, health economic audits of trial protocols, developing budget impact models, sourcing health outcomes and resource data, and undertaking literature reviews.
Prior to joining Labcorp Drug Development, Oona worked at the Centre for Health Economics Research and Evaluation (CHERE) at the University of Technology Sydney (UTS) as a PBAC submission evaluator, working closely with both the ESC and PBAC Secretariats.
Oona also has experience in developing MSAC Assessment Reports, PICO confirmations and critiques. Oona’s technical understanding of medical devices and services stems from her background as a Medical Physicist based at Liverpool Hospital’s Cancer Therapy Centre and the PET and Nuclear Medicine Department, Royal Price Alfred Hospital. Oona has also gained extensive experience in regulatory affairs from working within the pharmaceutical industry including the development of complex regulatory strategies for drug reformulation and split dosing. She has registered many new medicines and devices with Australia’s TGA and New Zealand’s Medsafe.
Oona received a Master’s of Public Health (Health Economics Major with High Distinction) and a Bachelor of Science (Hons) in Applied Physics from UTS.
Contact Us
MARKET ACCESS AND PHASE IV SOLUTIONS (ASIA-PACIFIC)
Suite 3.02 (Level 3, Building A)
97 Waterloo Road, Macquarie Corporate Centre
Macquarie Park NSW 2113
Australia
Tel: +61 2 8879 2000
.png){kind=icon}
